Discovery of a previously unknown heart muscle protein and how it affects mechanisms related to heart failure may lead to further treatments for cardiovascular disease.
Discovery of a previously unknown heart muscle protein and how it affects mechanisms related to heart failure may lead to further treatments for cardiovascular disease, according to a study published in Nature Communications.
Cardiologists Dr Matthias Eden and Professor Norbert Frey, from the University of Kiel in Germany, have recently discovered the Myoscape/FAM40B/STRIP2 protein, and how it directly affects the L-type calcium channel (LTCC). Specifically, the Myoscape protein influences calcium metabolism and the pumping ability of the heart muscle cell.
“In the absence of Myoscape, heart muscle cells in the model system develop a serious impairment of calcium channel metabolism, ultimately leading to progressive heart failure,” Frey said in a statement.
Combined with the protein actinin 2, Myoscape stabilizes the LTCC in the heart muscle cell at the necessary position within the cell membrane. Using Myoscape-depleted morphant zebrafish and Myoscape knockout mice, the researchers noted that without the Myoscape protein the calcium channel metabolism of the heart muscle cells became impaired and progressed to advanced heart failure. The mice, for example, depicted a reduction in LTCC currents, cell capacity, and calcium current densities.
When artificially increasing the levels of Myoscape, the researchers saw that the calcium channel currents increased as well. As such, Myoscape seems to restore previously decreased calcium currents in failing heart muscle cells.
“Since patients with severe heart failure also exhibit reduced levels of Myoscape protein in the heart, we believe that we have here discovered a critical new mechanism for the genesis of heart failure,” Frey said. With this dual discovery, it is possible that innovative new treatments will follow.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More
2 Commerce Drive
Cranbury, NJ 08512